You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,717,763


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,717,763
Title:Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
Abstract: Cells derived from human umbilical cords are disclosed along with methods for their therapeutic use. Isolation techniques, culture methods and detailed characterization of the cells with respect to their cell surface markers, gene expression, and their secretion of trophic factors are described.
Inventor(s): Mistry; Sanjay (Downingtown, PA), Kihm; Anthony J. (Princeton, NJ), Harris; Ian R. (Radnor, PA), Harmon; Alexander M. (Clifton, NJ), Messina; Darin J. (Downingtown, PA), Seyda; Agnieszka (Edison, NJ), Yi; Chin-Feng (Hillsborough, NJ), Gosiewska; Anna (Skillman, NJ)
Assignee: DEPUY SYNTHES PRODUCTS, INC. (Raynham, MA)
Application Number:14/018,842
Patent Claims:1. A method of enhancing the yield of cells isolated from human umbilical cord tissue, the method comprising the steps of: (a) obtaining umbilical cord tissue; (b) removing substantially all of the blood from the tissue to yield umbilical tissue substantially free of blood; (c) dissociating said umbilical tissue substantially free of blood by mechanical dissociation; (d) digesting the dissociated tissue with a mixture of enzymes comprising a metalloprotease, neutral protease and mucolytic enzyme, wherein the mixture of enzymes is a mixture of collagenase, dispase and hyaluronidase; (e) isolating umbilicus-derived cells from the digested tissue; (f) resuspending the isolated umbilicus-derived cells in a growth medium; and (g) culturing the isolated umbilicus-derived cells for about 10 to 100 hours to obtain a homogenous population of isolated umbilicus-derived cells, wherein the isolated umbilicus-derived cells of the homogenous population are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of other phenotypes, has increased expression, relative to a human fibroblast, mesenchymal stem cell, or iliac crest bone marrow cell, of a gene for interleukin 8, reticulon 1 and chemokine (C-X-C motif) ligand 3, and do not produce CD117.

2. The method of claim 1, wherein the removing step comprises removal of free or clotted blood by one or more of washing, suctioning, blotting, centrifugal separation, or enzymatic removal.

3. The method of claim 1, wherein the digestion step comprises incubating the dissociated tissue with the mixture of enzymes at about 37.degree. C.

4. The method of claim 1, wherein the digestion step comprises incubating the dissociated tissue with the mixture of enzymes for one or more hours.

5. The method of claim 1, wherein the population of isolated cells produces each of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C.

6. The method of claim 1, wherein the population of isolated cells does not produce any of CD31, CD34, CD45, CD80, CD86, CD141, CD178, B7-H2 or HLA-DR, DP,DQ, as detected by flow cytometry.

7. The method of claim 1, wherein the population of isolated cells can expand in the presence of oxygen from about 5% to about 20%.

8. The method of claim 1, wherein the population of isolated cells can expand for at least 40 doublings in culture.

9. The method of claim 1, wherein the population of isolated cells can expand to generate at least about 10.sup.17 cells in less than about 65 days in culture when seeded at about 5.times.10.sup.3 cells/cm.sup.2 of culture vessel surface.

10. The method of claim 1, wherein the population of isolated cells require L-Valine for growth.

11. The method of claim 1, wherein the population of isolated cells grows in the presence of from about 2% to about 15% Fetal Bovine Serum.

12. The method of claim 1, wherein the population of isolated cells grows in the presence or absence of one or more added growth factors selected from EGF, FGF, PDGF, VEGF, IGF and LIF.

13. The method of claim 1, wherein the population of isolated cells adheres and expands on a coated or uncoated tissue culture vessel.

14. The method of claim 1, further comprising expanding the population of isolated umbilicus-derived cells in culture for about 10 days to confluence.

15. The method of claim 1, wherein the cells are able to differentiate to a hepatocyte phenotype, an adipogenic phenotype, a pancreatic phenotype, a chondrogenic phenotype, and a cardiomyocyte phenotype.

16. A method of enhancing the yield of cells isolated from human umbilical cord tissue, the method comprising the steps of: (a) removing substantially all of the blood from post-partum umbilical cord tissue to yield umbilical tissue substantially free of blood; (b) dissociating said umbilical tissue substantially free of blood by mechanical dissociation; (c) isolating umbilicus-derived cells by digesting the dissociated tissue with a mixture of enzymes comprising a metalloprotease, neutral protease and mucolytic enzyme, wherein the mixture of enzymes is a mixture of collagenase, dispase and hyaluronidase; (d) resuspending the isolated umbilicus-derived cells in a growth medium; and (e) culturing the isolated umbilicus-derived cells for about 10 to 100 hours to obtain a homogenous population of isolated umbilicus-derived cells, wherein the isolated umbilicus-derived cells of the homogenous population are capable of self-renewal and expansion in culture, have the potential to differentiate into at least a hepatocyte phenotype, an adipogenic phenotype, a pancreatic phenotype, a chondrogenic phenotype, and a cardiomyocyte phenotype, has increased expression, relative to a human fibroblast, mesenchymal stem cell, or iliac crest bone marrow cell, of a gene for interleukin 8, reticulon 1 and chemokine (C-X-C motif) ligand 3, and do not produce CD 117.

17. The method of claim 1, wherein the isolated umbilicus-derived cells of the homogeneous population secrete MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1b, RANTES, and TIMP1, and do not secrete SDF-lalpha, TGF-beta2, ANG2, PDGFbb, MIP1a, and VEGF.

18. The method of claim 16, wherein the isolated umbilicus-derived cells of the homogeneous population secrete MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1b, RANTES, and TIMP1, and do not secrete SDF-lalpha, TGF-beta2, ANG2, PDGFbb, MIP1a, and VEGF.

Details for Patent 9,717,763

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 05/05/2004 ⤷  Try a Trial 2023-06-27
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 12/02/2004 ⤷  Try a Trial 2023-06-27
Amphastar Pharmaceuticals, Inc. AMPHADASE hyaluronidase Injection 021665 10/26/2004 ⤷  Try a Trial 2023-06-27
Akorn, Inc. HYDASE hyaluronidase Injection 021716 10/25/2005 ⤷  Try a Trial 2023-06-27
Smith & Nephew, Inc. SANTYL collagenase Ointment 101995 06/04/1965 ⤷  Try a Trial 2023-06-27
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.